THE LAWSUIT: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents ...

THE LAWSUIT: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents ...

LOS ANGELES, April 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA) investors of a class action representing ...

THE LAWSUIT: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents ...

Bank of America reiterated their underperform rating on shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) in a research report sent to investors on Wednesday, MarketBeat reports.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Neumora To Contact Him Directly To Discuss Their Options As ...

Analyst Price Forecast Suggests 644.56% Upside As of March 19, 2025, the average one-year price target for Neumora Therapeutics is $6.80/share. The forecasts range from a low of $2.02 to a high of ...

BofA double downgraded Neumora Therapeutics (NMRA) to Underperform from Buy with a price target of $1, down from $7. The firm is taking a more conservative view on the company’s lead navacaprant ...

THE LAWSUIT: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on ...

NEW YORK, April 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA ) of a class action ...

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to ...

EntryPoint Capital LLC purchased a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) in the fourth quarter, according to its most recent filing with the SEC.The fund purchased ...